Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BPX-501||rivogenlecleucel||BPX-501 comprises allogeneic T-cells transduced with a vector encoding inducible Casp9 that is linked to a drug binding domain, which enables induction of Casp9 with AP1903 if GVHD develops, resulting increased Casp9 expression and induction of T-cell death (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03807063||Phase I||Rimiducid BPX-501||Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant||Suspended|
|NCT02065869||Phase Ib/II||BPX-501 Rimiducid||Safety Study of Gene Modified Donor T-cells Following TCR Alpha Beta Depleted Stem Cell Transplant||Active, not recruiting|
|NCT02786485||Phase I||Rimiducid BPX-501||Study of Matched Unrelated Donor T Cell Infusion for Hematologic Malignancies After Allo-HSCT||Withdrawn|
|NCT01744223||Phase Ib/II||Rimiducid BPX-501||Safety Study of Gene Modified Donor T-cells Following Partially Mismatched Stem Cell Transplant||Active, not recruiting|
|NCT02487459||Phase I||BPX-501 Rimiducid||Safety Study of Gene Modified Donor T-Cells in Adults With Advanced Hematologic Malignancies||Withdrawn|